Trick or Treat: Curative Management of Esophageal Squamous Cell Carcinoma of a COVID-positive Patient

Saqib Raza Khan, Saad Nasir, Muhammad Nauman Zahir, Yasmin Abdul Rashid


The novel coronavirus pneumonia COVID-19 which is reportedly caused by SARS-CoV-2 infection can potentially lead to a course of clinical symptoms and fatal illnesses. Reported first in 2019, it has now affected more than 596,873,121 people, worldwide. In addition to its clinical manifestation in humans, the COVID-19 virus in cancer patients is significantly declining a positive prognosis. In the time of an ongoing global pandemic, oncologists are struggling to provide appropriate care to cancer patients due to their increased susceptibility to severe complications of COVID-19 which can be attributed to their immunosuppressed status caused by the malignancy and anticancer treatments. Similarly, the lack of literature, evidence, and consensus on whether to give antineoplastic agents to patients with active COVID-19 infection pose a unique challenge for physicians. In this article, we present a case of a 47-year-old female who was diagnosed with squamous cell carcinoma of the esophagus and later tested positive for SARS-CoV-2. Under unanimous decision, oncological treatment for the malignancy was initiated with a combination of chemotherapy and radiation without a consequential delay as per multidisciplinary tumor board (MDT) meeting decision which results in clinical improvement.


Covid-19, Esophagus, Squamous cell, Cancer, Treatment

Full Text:



Lekhraj Rampal M, Seng LB: Coronavirus disease (COVID-19) pandemic. Med J Malays. 2020, 75:95.

Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, et al.: Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. The. Lancet Oncology. 2020, 21:893-903.

Zeng R, Zhang X, Qin Z, Liu W: An unusual case report of primary cerebellar T-cell lymphoma and review of the literature. Interdisciplinary Neurosurgery. 2021, 101063:

Giesen N, Sprute R, Rüthrich M, Khodamoradi Y, Mellinghoff SC, Beutel G, et al.: Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). European Journal of Cancer. 2020, 140:86-104.

Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al.: Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. The. Lancet. 2020, 395:1907-18.

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al.: Global cancer observatory: cancer today. Lyon: International Agency for Research on Cancer; 20182020.

Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335–337

Wang H, Zhang L. Risk of COVID-19 for patients with cancer. Lancet Oncol. 2020;21:E181

Tartarone A, Lerose R: COVID-19 and cancer care: what do international guidelines say?. Medical Oncology. 2020, 37:1-5.

You B, Ravaud A, Canivet A, Ganem G, Giraud P, Guimbaud R, et al.: The official French guidelines to protect patients with cancer against SARS-CoV-2 infection. The. Lancet Oncology. 2020, 21:619-21.

Al‐Shamsi HO, Alhazzani W, Alhuraiji A, Coomes EA, Chemaly RF, Almuhanna M, et al.: A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID‐19) pandemic: an international collaborative group. The oncologist. 2020, 25:936.

National Institute for Health and Care Excellence. COVID-19 rapid guideline: delivery of systemic anticancer treatments. March 20, 2020. Available at: Accessed March 26, 2020.



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

2013-2023 (CC-BY) Australian International Academic Centre PTY.LTD.

Advances in Bioscience and Clinical Medicine